Study Of Ispinesib In Subjects With Breast Cancer
Completed · Phase 2
Conditions studied: Neoplasms, Breast
In brief
The purpose of this research study is to find how breast cancer responds to the investigational drug, Ispinesib. An investigational drug is a drug that has not been approved by the Food and Drug Administration (FDA) and is available for research use only. In particular, this study will try is to find the answers to the following research questions: 1. Does breast cancer respond to Ispinesib? 2. What are the side effects of Ispinesib? 3. How much Ispinesib is in the blood at specific times after it is taken?
Key facts
- Study ID
- NCT00089973
- Run by
- GlaxoSmithKline
- People needed
- 50
- Starts
- 2004-06-30
- Expected to finish
- 2006-08-25
- Last updated by the study team
- 2018-02-26
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Stage IIIB or Stage IV breast cancer
- Previously received anthracycline and taxane therapy
You may not qualify if…
- Actively receiving anti-cancer therapy agent(s).
Where it is running
- GSK Investigational Site — Jacksonville, Florida, United States
- GSK Investigational Site — Indianapolis, Indiana, United States
- GSK Investigational Site — Chapel Hill, North Carolina, United States
- GSK Investigational Site — Pittsburgh, Pennsylvania, United States
- GSK Investigational Site — Brussels, Belgium
- GSK Investigational Site — Bandar Tun Razak, Cheras, Malaysia
- GSK Investigational Site — Bandar Tun Razak, Cheras, Malaysia
- GSK Investigational Site — Singapore, Singapore
- GSK Investigational Site — Singapore, Singapore
- GSK Investigational Site — Southampton, Hampshire, United Kingdom
- GSK Investigational Site — Manchester, Lancashire, United Kingdom
- GSK Investigational Site — Newcastle upon Tyne, Northumberland, United Kingdom
- GSK Investigational Site — London, United Kingdom
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.